Multi-Cancer Vaccine Singapore: NUS NICER Nanovaccine Progress | AcademicJobs
Singapore researchers at NUS advance multi-cancer vaccine development with NICER nanovaccine, targeting cancer stem cells to prevent recurrence.
No reviews yet. Be the first to rate Qing!
Dr. Qing You is affiliated with the Department of Diagnostic Radiology at the Yong Loo Lin School of Medicine, National University of Singapore. He is the first author of the 2025 paper titled "A nanovaccine targeting cancer stem cells and bulk cancer cells for postoperative cancer immunotherapy," published in Nature Nanotechnology. The research describes a nanovaccine approach developed in collaboration with researchers from NUS Medicine and the National Center for Nanoscience and Technology, Chinese Academy of Sciences, aimed at targeting both bulk cancer cells and cancer stem cells for postoperative cancer immunotherapy in models including breast cancer and melanoma.
Singapore researchers at NUS advance multi-cancer vaccine development with NICER nanovaccine, targeting cancer stem cells to prevent recurrence.